news

Selected as Innovation Showcase Finalists 2025

by

We're Finalists in 2025!

The annual Animal Health, Nutrition and Technology Innovation event is the global premier investment forum showcasing the most exciting investment opportunities in animal health and nutrition. It connects those businesses with financial investors and strategic corporate partners.

Competition for selection as a Showcase finalist is intense. There were 8 international selection committee members who have an extensive breadth of experience and knowledge across animal health and nutrition industries.

After a 5-minute presentation, the audience will select a winner.

Selection as a Showcase Finalist alone is significant recognition by experts in the field of the potential of Snoretox products for the treatment of BOAS and other conditions in the Veterinarian sector.

Selected as Finalist Animal Health, Nutrition and Technology Innovation Europe 2025

Snoretox Ltd is excited to be declared an Innovation Showcase Finalist in the Companion Animal section at the Animal Health, Nutrition and Technology Innovation Europe 2025 Convention, 10-12 February 2025 in London, UK, @AHInnovation #AHTNI

Premier singles out Snoretox in Breakthrough Victoria Funding Announcement

by

June 2022.

Snoretox was today singled out in the announcement by Premier Dan Andrews and Treasurer Tim Pallas of $100 million for the Breakthrough Victoria – University Innovation Platform. 

Snoretox is another example of a company commercialising RMIT-developed technology – a novel muscle toning toxin-based therapeutic for treating sleep apnea and snoring, as well as a range of other weak muscle conditions such as incontinence.

Department of Premier and Cabinet

Breakthrough Victoria is backing great ideas that will save lives, change the way we live and provide jobs for the generations that will follow us.

Daniel Andrews

Read the full media release here

More

Snoretox Awarded “Barrier to Innovation” Waiver by the FDA CVM (USA Federal Drug Agency).

by

Innovative Australian Drug receives Break-through Therapy “Barrier to Innovation” Waiver by the FDA CVM  (USA Federal Drug Agency).

The FDA CVM is the FDA’s veterinarian department.

The assessment criteria are

  • Innovation: a drug must be highly innovative, novel, a medical break-through.
  • Efficacy: Is there sufficient information for proof of concept in a validated in vitro system or in the target animal or an animal model of the target animal (e.g., laboratory rodent species)?
  • Small-Medium Company: Is the company below $20 million in market size.

 

We were able to satisfy the criteria and examiners with a detailed application outlining the scientific evidence, they do not give these out lightly.

This success adds serious credibility to our dealings with the government, regulators and the market.

I would like to thank our USA FDA CVM Consultants Schafer and Associates for all their assistance and guidance to date.

a/Prof Anthony Sasse,

What others are saying